Biogen Results: Time To Change The Paradigm In Alzheimer's Disease (NASDAQ:BIIB) | Seeking Alpha
Current clinical trials for the treatment of Alzheimer's disease (as of... | Download Table
Of Four Aβ Antibodies, Only Aducanumab Stems Tide of Toxic Oligomers | ALZFORUM
IJMS | Free Full-Text | Revisiting the Amyloid Cascade Hypothesis: From Anti-Aβ Therapeutics to Auspicious New Ways for Alzheimer's Disease | HTML
Amyloid-beta immunotherapy: the hope for Alzheimer disease?
xmlinkhub
Alzheimer's disease drug development pipeline: 2017 - Cummings - 2017 - Alzheimer's & Dementia: Translational Research & Clinical Interventions - Wiley Online Library
S-1/A
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody | Alzheimer's Research & Therapy | Full Text
View of Immunotherapy Targeting Amyloid-β Peptides in Alzheimer's Disease | Exon Publications
LATEST FINDINGS ON LECANEMAB - CLINICAL EFFICACY, ARIA RATES, BIOMARKERS RELATIONSHIP TO CLINICAL OUTCOMES AND DOSING REGIMENS - PRESENTED AT AD/PD™ 2022 ANNUAL MEETING
Aβ-Immunotherapeutic strategies: a wide range of approaches for Alzheimer's disease treatment | Expert Reviews in Molecular Medicine | Cambridge Core
Frontiers | Linking Molecular Pathways and Large-Scale Computational Modeling to Assess Candidate Disease Mechanisms and Pharmacodynamics in Alzheimer's Disease | Frontiers in Computational Neuroscience
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody | Alzheimer's Research & Therapy | Full Text
Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer's disease: a systematic review - ScienceDirect
The amyloid cascade and Alzheimer's disease therapeutics: theory versus observation | Laboratory Investigation
Anti-Amyloid-β Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise - Biological Psychiatry
Monoclonal antibodies against β-amyloid currently in phase III clinical... | Download Scientific Diagram
Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval | Semantic Scholar
S-1
EISAI ANNOUNCES THE START OF THE FIRST CLINICAL STUDY OF BAN2401, A NOVEL MONOCLONAL ANTIBODY TARGETING THE NEUROTOXIC PROTOFIBRILS BELIEVED TO CAUSE ALZHEIMER'S DISEASE | News Release：2010 | Eisai Co., Ltd.
The Development of Pharmacological Therapies for Alzheimer's Disease | SpringerLink
Advisory Council January 2018 Meeting Presentation: Overview on NIA Preclinical Pipeline | ASPE
IJMS | Free Full-Text | Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease | HTML
